Since S100a8/9 expression has been shown to correlate with clinical severity in IBD patients, and their neutralization can attenuate colitis pathology, targeting JAK2-STAT3 signaling axis may represent potential therapeutic strategies to regulate gut microbiome and inflammation. Here, S100A8 is linked to colitis.